Please ensure Javascript is enabled for purposes of website accessibility

United Therapeutics reports loss in 4Q

United Therapeutics Corp., of Silver Spring, saw its bottom line plunge in 2013’s fourth quarter, reporting a net loss of $30.3 million, or 60 cents per diluted share, versus net income of $83.25 million, or $1.60 per diluted share, for the year-before period.

Revenue totaled $289 million in the 2013 quarter versus $243.8 million in the prior-year period.

Analysts surveyed by Thomson Reuters had forecast, on average, earnings of $1.51 per share on revenue of $295.43 million.

Research and development expenses more than tripled year-to-year, and selling, general and administrative expenses almost quadrupled.

United Therapeutics develops and markets treatments for unmet medical needs of patients with chronic and life-threatening conditions.